Should Men with Serum Prostate-Specific Antigen ≤4 ng/ml and Normal Digital Rectal Examination Undergo a Prostate Biopsy?

• Published in: Oncology Vol. 70; no. 2; pp. 81 - 89
• Main Authors: Pepe, Pietro, Panella, Paolo, D’Arrigo, Letterio, Savoca, Francesco, Pennisi, Michele, Aragona, Francesco
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland 01.02.2006
• Subjects: Review; Screening; Radical prostatectomy; Biopsy; Prostate-specific antigen; Prostate cancer
• ISSN: 0030-2414; 1423-0232
• DOI: 10.1159/000092583

The clinical significance of a prostate cancer (PCa) cannot be determined solely by tumor volume (≤0.5 cm 3 ), as small tumors of higher Gleason grade and tumors occurring in younger men may become clinically significant even though the initial volume at diagnosis is small. A certain number of these minimal cancers are likely to remain clinically insignificant; however, it is unpredictable how many can progress beyond the curable stage by the time there is a rise in serum prostate-specific antigen (PSA) values. Compared to clinically detected PCa, PCa detected exclusively by PSA screening (clinical stage T1c) are less likely to be advanced but no more likely to be insignificant in terms of volume, pathologic stage, and Gleason pattern. Only 10–15% of PSA-detected cancers have the features of PCa found at autopsy or in cystoprostatectomy specimens. Actually, 25–30% of PCa are detected with PSA values between 2.5 and 4 ng/ml, and most of these cancers are clinically significant. Evidence from both retrospective and longitudinal studies has shown that the risk of a PCa is dependent on the patient’s age and the initial serum PSA. This allows an individualized approach to PCa screening programs, and PSA cutoff values for biopsy indication may be lowered in selected patients.